BPC-157 Treats Experimental Esophagitis With Sphincter Failure in Rats

BPC-157 healed prolonged experimental esophagitis with sphincter failure in rats, improving both mucosal healing and sphincter function — addressing the complete pathology of reflux disease.

Petrovic, Igor et al.·Journal of pharmacological sciences·2006·Moderate EvidenceAnimal StudyAnimal Study
RPEP-01177Animal StudyModerate Evidence2006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

BPC-157 healed prolonged esophagitis and improved lower esophageal sphincter function in a rat reflux model with sphincter failure, addressing both mucosal damage AND the mechanical cause (sphincter dysfunction) of reflux disease.

Key Numbers

How They Did This

animal-study study on bpc-157, gut-healing.

Why This Research Matters

Relevant for bpc-157, gut-healing.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding BPC-157 healed prolonged esophagitis and improved lower esophageal sphincter function in a rat reflux model with sphincter failure, addressing both mu
Evidence Grade:
moderate evidence.
Study Age:
Published in 2006.
Original Title:
An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.
Published In:
Journal of pharmacological sciences, 102(3), 269-77 (2006)
Database ID:
RPEP-01177

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What was studied?

BPC-157 Treats Experimental Esophagitis With Sphincter Failure in Rats

What was found?

BPC-157 healed prolonged experimental esophagitis with sphincter failure in rats, improving both mucosal healing and sphincter function — addressing the complete pathology of reflux disease.

Read More on RethinkPeptides

Cite This Study

RPEP-01177·https://rethinkpeptides.com/research/RPEP-01177

APA

Petrovic, Igor; Dobric, Ivan; Drvis, Petar; Shejbal, Drazen; Brcic, Luka; Blagaic, Alenka Boban; Batelja, Lovorka; Kokic, Neven; Tonkic, Ante; Mise, Stjepan; Baotic, Tomislav; Staresinic, Mario; Radic, Bozo; Jakir, Ana; Vuksic, Tihomir; Anic, Tomislav; Seiwerth, Sven; Sikiric, Predrag. (2006). An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.. Journal of pharmacological sciences, 102(3), 269-77.

MLA

Petrovic, Igor, et al. "An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.." Journal of pharmacological sciences, 2006.

RethinkPeptides

RethinkPeptides Research Database. "An experimental model of prolonged esophagitis with sphincte..." RPEP-01177. Retrieved from https://rethinkpeptides.com/research/petrovic-2006-an-experimental-model-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.